BioSpace News Archive

A high-ranking Mobile Gamma Cameras market survey report can be referred confidently when it is about taking important business decisions.

Viral Vector Purification market research report identifies, and analyses the emerging trends along with major drivers, restraints, challenges and opportunities in the market.

For days, and even years, after someone suffers a stroke or traumatic brain injury, they have an increased risk of developing epilepsy.

Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.

Avivagen Inc. announces that it has closed the third tranche of its previously announced non-brokered private placement financing through the issuance of units of the Company at a price of $0.20 per Unit .

CANbridge Pharmaceuticals Inc. announced that it has formed a Complement Disease Scientific Advisory Board focused on the global development of CAN106, a novel, long-acting monoclonal antibody directed against C5 complement.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis via press release after market close on Tuesday, July 12, 2022.

Data Bridge Market Research Published Latest Global Nasal Spray Market Study by in-depth analysis about current scenario, the Market size, demand, growth pattern, trends, and forecast.

Surgalign Holdings, Inc. announced that it has granted restricted stock unit awards to one employee, who was not an executive officer, as an inducement for them to accept employment with Surgalign, and representing the right to receive, in the aggregate, up to 9,259 shares of Surgalign common stock.

Today, after months of effort by the American Pharmacists Association (APhA) and other stakeholders, FDA has updated the EUA for the COVID-19 oral antiviral, Paxlovid, to permit pharmacists to order and prescribe Paxlovid under certain conditions.